April 1, 2020

ACE Inhibitors & ARBs: Wading Into the Unknown of COVID-19 There has been some dissent lately about the role angiotensin-converting enzyme plays in the COVID-19 infections. The chemistry can be quite confusing, making it easy to see why it has caused controversy. Read more

Birth Weight Predicts Heart Failure in Mothers A new study presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) has revealed a low birth weight could serve as an indicator for increased risk of cardiovascular disease in mothers.

To Reduce Risk of Heart Arrhythmias, Eat More Meat A new study examining the impact of increased protein intake in older women has returned promising results showing a potential reduction in the risk of one of the most common cardiovascular conditions.

US Adult E-Cigarette Use Climbing, Despite Cardiology Health Concerns Electronic cigarette use has grown to approximately 1 in every 20 US adults, according to new findings presented virtually at the American College of Cardiology (ACC) 2020 Scientific Sessions this week.

Statins Could Reduce Cardiotoxicity, Heart Failure from Chemotherapy While chemotherapy with anthracycline and trastuzumab have been linked to cardiotoxicity, new research is suggesting a common cardiovascular medication could help offset some of the negative impact on cardiovascular health in breast cancer patients.

Specific Cancer Types May Carry Increased Risk for Atrial Fibrillation While multiple previous studies have detailed the additional risk of arrhythmias associated with patients who have cancer, new data is shedding light on which forms of cancer carry the greatest risk.

IN CASE YOU MISSED IT….

Metformin Protects Hearts of Diabetic Transplant Recipients Transplanted hearts are protected by the diabetes drug Metformin, when the recipient is diabetic a studyin the Journal of the American College of Cardiology finds.

Cardiology Organizations Advise on ACE Inhibitors, ARBs Use During COVID-19 In the face of the worldwide coronavirus (COVID-19) pandemic, 4 of the largest cardiology organizations are advising patients receiving treatment with ACE inhibitors (ACE-i) and angiotensin receptor blockers (ARBs) they should not be discontinuing treatment unless it is recommended by their physician. Find out more.

We want to hear from you! Did you love an article you read in Practical Cardiology? Disagree with an author’s conclusions? Want to share how you solved an issue in your practice? Then Practical Cardiology editors want to hear from you! Please send your comments to GCudaKroen@mjhlifesciences.com.